Intrauterine adhesion (IUA) is a serious complication caused by excessive fibrosis resulting from endometrial repair after trauma. The traditional Chinese medicine Tiaoshen Tongluo recipe (TTR) contains ingredients associated with the alleviation of fibrosis. The transforming growth factor-β1 (TGF-β1)/Smad pathway is thought to mediate fibrosis in IUA. In this study, we evaluated the influence of TTR on endometrial fibrosis in a rat model of IUA and in TGF-β1-stimulated endometrial stromal cells (ESCs). TTR was found to alleviate the level of endometrial fibrosis in a rat model of IUA. A higher number of collagen fibers and greater damage were observed in the endometrial tissue of untreated rats compared to those treated with TTR. The expression of TGF-β1, Smad2, Smad3, and Smad4 was upregulated following IUA, whereas Smad7 expression was downregulated. TTR lowers the expression of TGF-β1, Smad2, Smad3, and Smad4 but increases the expression of Smad7 in vivo, indicating that TTR can modulate the expression of the TGF-β1/Smad pathway to mediate fibrosis. In ESCs, the phosphorylation of Smad2 and Smad3 and upregulation of Smad4 were induced by TGF-β1 whereas the expression of Smad7 was inhibited. Administration of TTR reduces the phosphorylation of Smad2 and Smad3, increases Smad4 expression induced by TGF-β1, and promotes the expression of Smad7. TTR modulates the TGF-β1/Smad pathway to alleviate the generation of fibrotic tissue in response to IUA.
15 January 2025 in Computational Biology and Chemistry
Psoriasis is a common clinical skin inflammatory disease. Haitang-Xiaoyin Mixture (HXM) represents a traditional Chinese medicine formulation utilized clinically for the management of psoriasis, which can reduce the psoriasis area and severity index (PASI) score, IL-23 and IL-23 levels in patients with psoriasis. However, the main active components and specific targets of HXM in the treatment of psoriasis and the relevant mechanisms of action are not clear. Therefore, in the study we aimed to elucidate the mechanistic basis of HXM's therapeutic action in psoriasis treatment through the application of bioinformatics, network pharmacology, machine learning and molecular docking methodologies. The psoriasis-related genes were obtained from the Gene Expression Omnibus (GEO) dataset, which psoriasis-associated disease genes were identified utilizing the GeneCard and DisGeNEt databases. The active ingredients of HXM were retrieved from HERB and TCMSP databases. Protein-Protein Interactions (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted to identify potential targets and signaling pathways. Psoriasis key targets were determined using LASSO, SVM-RFE, and Boruta algorithms, followed by Receiver Operating Characteristic (ROC) analysis. Key targets were GESA enriched and analyzed for transcription factors and immune cell infiltration. Finally molecular docking and molecular dynamics simulations were performed to validate the binding of active compounds to core targets, elucidating their mechanism of action. A total of 233 psoriasis-related targets and 290 drug targets were identified. After data set crossover, 37 pharmacodynamic targets were obtained. PPI network topology analysis revealed 12 core targets. GO and KEGG enrichment analysis suggested that HXM may regulate angiogenesis, chemokine receptor binding process, as well as IL-17 and TNF related signaling pathways. Machine algorithm screening identified two psoriasis characteristic genes: CXCL2 and CXCR4. Immune infiltration results demonstrated a significant positive correlation between the characteristic genes and M1 macrophages, along with identification of the top 20 transcription factors involved. Quercetin and triptolide were recognized as potential core components of HXM for treating psoriasis based on their molecular docking and molecular dynamics simulation results confirming strong binding abilities with CXCL2 and CXCR4 respectively. This study elucidates the active constituents, potential targets, and underlying pathways involved in the therapeutic effects of HXM for psoriasis. Specifically, CXCL2 and CXCR4 are identified as key targets, with quercetin and triptolide representing crucial compounds exerting their effects on these targets.
1 December 2014 in Journal of Traditional Chinese Medicine
Objective: To determine the effects of Anshendingzhi decoction (ASDZD) on depression, to compare ASDZD with Danzhixiaoyao pill (DZXYP), and to provide evidence for the clinical treatment of depression with Traditional Chinese Medicine. Methods: Seventy-eight patients with depression were enrolled from 2011 to 2013 in this double-blinded study. Patients were randomly divided into two groups: ASDZD (treatment group, n=39) and DZXYP (control group, n=39). Hamilton Depressive Scale and TCM Syndrome Differentiation Scale were used to assess depression and efficacy before treatment and 2, 4, and 6 weeks after treatment. The Treatment Emergent Symptoms Scale (TESS) was used to evaluate adverse reactions, observe, and record treatment outcomes. Results: ASDZD was significantly more effective than DZXYP. There were significant differences between the two groups in terms of recovered patients, overall response rate, and TESS score (all P<0.05). Conclusion: ASDZD is an effective treatment for depression. ASDZD could improve clinical symptoms and warrants further clinical research and application.
Transforming growth factor-β (TGF-β) is one of the most complex and context-dependent cytokines in the immune system. Its signaling pathway regulates differentiation, functions, and microenvironment-specific adaptations of immune cells through Smad-dependent and Smad-independent pathways. In normal physiological conditions, TGF-β maintains immune tolerance, regulates T-cell fate determination, and participates in tissue repair. In pathological conditions, aberrant TGF-β signaling drives fibrosis, tumor immune evasion, and chronic inflammatory responses. In recent years, innovative technologies such as single-cell omics and spatial transcriptomics have revealed the dynamic characteristics of TGF-β signaling in different cell lineages and microenvironments. These techniques have deepened the understanding of its molecular circuits and immune regulatory networks. Therapeutic strategies targeting TGF-β, including receptor kinase inhibitors, bispecific antibodies, and nanotechnology-based delivery systems, have shown potential in disease models such as fibrosis and tumors, but still face challenges such as toxicity, side effects, and disease stage dependence. This article reviews the multidimensional mechanism of TGF-β signaling in immune homeostasis, fibrosis, and tumor progression; assesses its prospects and limitations as a therapeutic target; and proposes future directions for clinical translation through patient stratification and disease staging, precise nanodelivery, and combination therapy, providing a theoretical basis for precise intervention in immune-related diseases.